Table 2.
Goal Attainment at 1 Year
| Baseline Characteristics | Attained LDL-C Goal (N=3984) | Attained SBP Goal (N=3984) |
|---|---|---|
| Overall | 2066/3984 (51.9) | 2977/3984 (74.7) |
| Age, y | ||
| <65 | 1029/2085 (49.4) | 1623/2085 (77.8) |
| ≥ 65 | 1037/1899 (54.6) | 1354/1899 (71.3) |
| Sex, n (%) | ||
| Male | 1690/3087 (54.7) | 2343/3087 (75.9) |
| Female | 376/897 (41.9) | 634/897 (70.7) |
| Race, n (%) | ||
| Nonwhite | 788/1385 (56.9) | 1058/1385 (76.4) |
| White | 1266/2573 (49.2) | 1899/2573 (73.8) |
| Diabetes mellitus, n (%) | ||
| Yes | 909/1633 (55.7) | 1169/1633 (71.6) |
| No | 1157/2351 (49.2) | 1808/2351 (76.9) |
| BMI, kg/m2, n (%) | ||
| <30 | 1407/2693 (52.2) | 2035/2693 (75.6) |
| ≥ 30 | 642/1267 (50.7) | 927/1267 (73.2) |
| Current smoking, n (%) | ||
| Yes | 219/480 (45.6) | 354/480 (73.8) |
| No | 1842/3499 (52.6) | 2618/3499 (74.8) |
| High-intensity statin therapy,* n (%) | ||
| Yes | 843/1467 (57.5) | 1114/1467 (75.9) |
| No | 792/1542 (51.4) | 1171/1542 (75.9) |
| ≥2 Lipid-lowering medications,† n (%) | ||
| Yes | 182/355 (51.3) | 273/355 (76.9) |
| No | 1884/3629 (51.9) | 2704/3629 (74.5) |
| ≥2 Antihypertensive medications,† n (%) | ||
| Yes | 1439/2778 (51.8) | 2030/2778 (73.1) |
| No | 627/1206 (52.0) | 947/1206 (78.5) |
| Hypertension, n (%) | ||
| Yes | 1471/2890 (50.9) | 2087/2890 (72.2) |
| No | 588/1079 (54.5) | 878/1079 (81.4) |
| Prior MI, n (%) | ||
| Yes | 381/784 (48.6) | 615/784 (78.4) |
| No | 1677/3188 (52.6) | 2353/3188 (73.8) |
| Prior stroke, n (%) | ||
| Yes | 49/104 (47.1) | 73/104 (70.2) |
| No | 2017/3880 (52.0) | 2904/3880 (74.8) |
| Prior PCI, n (%) | ||
| Yes | 402/832 (48.3) | 645/832 (77.5) |
| No | 1662/3150 (52.8) | 2330/3150 (74.0) |
| Prior CABG, n (%) | ||
| Yes | 70/140 (50.0) | 113/140 (80.7) |
| No | 1996/3844 (51.9) | 2864/3844 (74.5) |
| SAQ angina frequency, n (%) | ||
| Any angina in past month (0–99) | 1300/2586 (50.3) | 1959/2586 (75.8) |
| No angina in past month (100) | 746/1354 (55.1) | 985/1354 (72.7) |
| SAQ summary score, n (%) | ||
| Poor to good (0–74) | 913/1836 (49.7) | 1402/1836 (76.4) |
| Good to excellent (75–100) | 1136/2108 (53.9) | 1546/2108 (73.3) |
| Morisky Green Levine Adherence Score, n (%) | ||
| Adherent | 1527/2860 (53.4) | 2135/2860 (74.7) |
| Nonadherent | 467/970 (48.1) | 731/970 (75.4) |
| Region, n (%) | ||
| Africa/Middle East/Pacifica | 36/78 (46.2) | 57/78 (73.1) |
| Asia | 709/1312 (54.0) | 1043/1312 (79.5) |
| North America | 539/897 (60.1) | 705/897 (78.6) |
| Europe | 632/1315 (48.1) | 939/1315 (71.4) |
| Latin America | 150/382 (39.3) | 233/382 (61.0) |
| Medication donation/reimbursement, n (%) | ||
| Yes | 459/807 (56.9) | 607/807 (75.2) |
| No | 1607/3177 (50.6) | 2370/3177 (74.6) |
BMI indicates body mass index; CABG, coronary artery bypass graft; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; SAQ, Seattle Angina Questionnaire; and SBP, systolic blood pressure.
*
High-intensity dose of rosuvastatin or atorvastatin.
†
Medications listed under the categories of lipid-lowering and antihypertensive medications from Table 1.